Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) represents a curative modality for many patients with advanced hematological malignancies. The effectiveness of this modality lies, in part, in providing an allogeneic effect and graft-versus-malignancy (GVM) response. In this situation, effector cells of donor origin recognize and eliminate malignant host cells that have survived a preparative cytotoxic conditioning regimen. The GVM effect first was described in leukemia patients, 1 ,2 but has also been documented in lymphoma and myeloma patients who have undergone an allo-HCT. 3 Unfortunately, this phenomenon often is associated with GVHD, the most common complication of allo-HCT, occurring in 50-70% of recipients of matched-related T cell replete grafts. 4 It has long been recognized that patients with chronic GVHD benefit from a decreased risk of disease relapse, 1, 2 suggesting that the GVM effect may be dependent upon the development of GVHD. Severe GVHD, however, is associated with a high incidence of morbidity and mortality and in clinical practice every attempt is made to prevent it.
Autologous hematopoietic cell transplantation (auto-HCT) also is an effective therapeutic strategy for a variety of hematological malignancies. [5] [6] [7] [8] Malignant disease recurrence, however, remains a significant problem after auto-HCT. Immunotherapy, which may offer a noncross-resistant anti-cancer mechanism compared to chemotherapy, represents a potential therapeutic approach for reducing the risk of relapse after auto-HCT.
An autoimmune syndrome similar to acute GVHD has been reported after auto-HCT, and has been termed the 'auto-aggression' syndrome or autologous GVHD (auto-GVHD). 9 Auto-GVHD tends to be milder than classical GVHD, most commonly involves the skin (rarely the gastrointestinal tract or liver) and often is self-limited. [9] [10] [11] [12] Auto-GVHD has been reported to occur both spontaneously and in subjects receiving post transplant immune modulation with CsA, IFN-g or the combination. 9, 13, 14 Experiments in rodents undergoing auto-HCT demonstrated that auto-GVHD could be elicited through use of CsA in the immediate post transplant setting. 15, 16 Later it was discovered that CsA directly impaired central tolerance in the thymus, thus fostering an environment favoring autoimmunity. 17, 18 Several groups subsequently have shown that auto-GVHD is dependent upon CD8 þ T cells which paradoxically recognize a self peptide from the invariant chain, termed CLIP, in association with an MHC class II molecule. While CsA clearly is important in the pathogenesis of auto-GVHD, others have suggested that the depletion of regulatory T cells (Tregs) which occurs after the preparative chemotherapy, in addition, may inhibit peripheral tolerance and contribute to the development of auto-GVHD. 19, 20 Thus, it appears that auto-GVHD may arise as a result of impaired immune tolerance, both central through treatment with CsA and peripheral through Treg cell depletion.
In recent years, clinical investigators desired to take advantage of this autoimmune phenomenon, hypothesizing that the induction of auto-GVHD potentially could augment the efficacy of auto-HCT via a GVM effect. Phase I and II studies were performed to evaluate the potential efficacy of post transplant immune modulation using CsA with or without IFN-g to induce auto-GVHD. 10, 14, [21] [22] [23] [24] [25] [26] We will review these data from a clinical and mechanistic perspective and speculate as to how auto-GVHD might be more effectively harnessed in future clinical trials.
Incidence and clinical characteristics
Auto-GVHD first was reported by Hood et al. 9 in 1987, who retrospectively noted the onset of spontaneous auto-GVHD in 7 of 96 patients undergoing auto-HCT between 1977 and 1984. Most cases were mild, self-limited and all cases were confined to the skin. A minority of patients required treatment with topical or systemic corticosteroids. Spontaneous auto-GVHD also has been described after peripheral blood auto-HCTs, 13 including use of positively selected CD34 þ stem cell grafts. It has been estimated that approximately 5-20% of patients will develop this syndrome spontaneously after auto-HCT, 9, 13 while in 20-100% of patients it may be induced after transplant using immune modulation with CsA, IFN-g or a combination of both. 10, 14, 19, 21, 22, 24, 26 Auto-GVHD generally appears within the first several weeks after auto-HCT, typically manifesting as a localized or more generalized erythematous maculopapular rash involving the face, trunk, extremities, palms and soles. The histopathologic appearance is inseparable from classic acute GVHD and rarely is greater than grade II in appearance. The course of auto-GVHD generally is self-limited and it often requires no treatment. An occasional patient may require therapy with either topical or systemic corticosteroids. Findings often persist for 1-3 weeks followed by a rapid dissipation of signs and symptoms. Skin involvement is most common, 9,10 while gastrointestinal or hepatic involvement is though to be much less frequent, 11, 12, 27 but may be underreported. For example, in a recent single-center retrospective analysis, Holmberg et al.
11 suggested a 13% incidence of intestinal auto-GVHD.
Animal models of auto-GVHD
In the late 1970s Rappeport et al. 27 reported the occurrence of GVHD in humans following syngeneic bone marrow transplantation, which prompted an exploration into the biologic mechanisms underlying this phenomenon, as major or minor histocompatibility antigen mismatches between donor and recipient were at that time thought to be absolutely required for the initiation of GVHD. Interestingly, Glazier et al. 13 developed a preclinical transplant model of auto-GVHD. Lethally irradiated rats treated with CsA followed by infusion of syngeneic or autologous marrow developed a syndrome indistinguishable from classical acute GVHD, including typical histopathologic changes noted in the skin, tongue, esophagus and liver of affected animals. These experiments provided initial evidence that differences in histocompatibility antigens were not absolutely required for the development of GVHD. Further evidence supporting the existence of auto-GVHD came with the isolation of autoreactive CD8
þ T cells in CsA-treated rodents that paradoxically recognized a commonly shared class II histocompatibility determinant. 16, 28 These autoreactive T cells lysed MHC class II-expressing tumor cells in vitro, suggesting a potential GVM effect of auto-GVHD. 28 Why did the use of a potent immunosuppressant agent lead to the development of an autoimmune disorder? The answer to this important question came from two groups which investigated the effect of CsA on developing thymocytes in lethally irradiated mice undergoing autologous transplantation. 17, 18 Both groups demonstrated that while CsA greatly reduced the number of mature, CD4 Nearly a decade later, reports in mice 29 and humans 30 demonstrated that CD8 þ T cell clones in auto-GVHD paradoxically recognized MHC class II molecules in association with a peptide from the invariant chain (CLIP). The T cell clones responsible for auto-GVHD isolated from rodents 29, 31 and humans 32, 33 were often restricted to specific TCR B-chain variable regions, suggesting that an antigenspecific expansion of self-reactive T cells was responsible for auto-GVHD.
Additional tumor specific antigens may play a role in the development of autologous graft versus malignancy mechanisms as shown by Borrello et al., 34 using a syngeneic transplant model. They demonstrated that when grafts from tumor bearing syngeneic donor mice were transplanted in a tumor bearing recipient (a model reminiscent of autologous transplant), tumor progression was delayed more than with infusion of grafts from tumor free syngeneic mice (a model reminiscent of syngeneic transplant). Table 1 shows data for studies reporting on spontaneous auto-GVHD after auto-HCT; the frequency appears to be approximately 5-20% of recipients. 9, 13 As mentioned above, Hood et al. 7 were the first to report spontaneously occurring auto-GVHD in several patients treated with bone marrow transplant at their center over a 7-year period. Spontaneous auto-GVHD also has been described after peripheral blood auto-HCTs, 13 including after infusions of positively selected CD34 þ stem cell grafts.
Spontaneous auto-GVHD

Clinical trials to induce auto-GVHD
Single-agent CsA Jones et al. 10 were the first group to report a phase I trial investigating the use of CsA after auto-HCT to induce auto-GVHD ( Table 2) . Five resistant or relapsed lymphoma patients who underwent auto-HCT with high-dose cyclophosphamide and total body irradiation (Cy-TBI) or busulfan and cyclophosphamide (Bu-Cy) were given CsA 1 mg/kg/day intravenously for 28 days. All five patients developed a typical rash consistent with GVHD that was confirmed as grade II GVHD on skin biopsy. Median onset was 11 days after marrow infusion and the duration of the auto-GVHD was 1-3 weeks. In two patients, the rash resolved spontaneously while two patients required treatment with intravenous corticosteroids. No patient developed diarrhea or liver function test abnormalities suggestive of gastrointestinal or hepatic involvement. One patient had evidence of autoreactive T cells against his own pretransplant lymphocytes and against those of a healthy volunteer. In vitro autoreactivity, blocked by preincubation of the target cells with an anti-DR antibody, resolved with clinical symptomatology.
This group performed a follow-up phase I CsA doseescalation study in AML patients undergoing purgedmarrow auto-HCT. 37 Nineteen AML patients in first, second or third complete remission received conditioning with Bu-Cy, followed by re-infusion of 4-hydroperoxycyclophosphamide (4HC)-treated marrow (an in vitro purging agent). Patients received CsA at three dose levels of 1, 2.5 and 3.75 mg/kg/day for up to 28 days after auto-HCT. Overall, 15/19 patients (79%) demonstrated skin histopathologic changes of auto-GVHD. Ten of 19 (53%) subjects developed cutaneous GVHD manifestations at a median (range) time to onset of 33 (14-49) days. The incidence, severity and duration of auto-GVHD were similar among the various CsA doses tested in this trial. CsA dose-reduction was necessary in several patients due to renal insufficiency that did not correlate with the assigned dose level (Serum or blood levels were not routinely monitored). Low doses of CsA were sufficient to induce auto-GVHD after auto-HCT but the small number of patients precluded definitive conclusions about the potential GVM effect of auto-GVHD.
Another trial from the Hopkins group 22 involved 51 advanced breast cancer patients undergoing auto-HCT using high-dose cyclophosphamide and thiotepa conditioning and a CsA dose-escalation similar to that used in their AML trial. 37 Seventy percent of patients developed skin auto-GVHD at a median of 15 days following auto-HCT. In all cases, the symptoms were mild and no patient required specific therapy. Contrary to the previous CsA dose-escalation study, higher doses of CsA in this investigation were correlated with an increased rate of Autologous graft-versus-host disease J Kline et al Table 2 Studies of induced auto-GVHD There was also a significant increase in episodes of documented sepsis in CsA-treated patients compared to controls. Disappointingly, there was no definitive benefit to developing auto-GVHD with regard to improved diseasefree or overall survival, and relapse rates were not reported. Giralt et al. 21 investigated the feasibility of CsA-induced auto-GVHD in 14 multiple myeloma patients undergoing auto-HCT. Patients were conditioned with thiotepa, busulfan and cyclophosphamide, and were given CsA for 28 days after auto-HCT. CsA blood concentrations were maintained between 50 and 150 ng/dl in the first sevenpatient cohort, and between 150 and 300 ng/dl in the next seven patients. Overall, the authors commented that the addition of CsA post-auto-HCT was well tolerated, although there was a statistically significant increase in grade II nephrotoxicity and hepatotoxicity in the CsA-treated patients compared with historical controls, requiring early withdrawal of CsA in seven patients after a median of 6 days. One patient developed clinically apparent auto-GVHD of the skin which responded to corticosteroids, while six others demonstrated histopathologic evidence of the syndrome on blind skin biopsy. The incidence of auto-GVHD was similar between the highand low-level CsA groups. Overall, three patients achieved an objective response to the treatment, and the 1-year disease-free and overall survival was 83±10%. The authors concluded that although the induction of auto-GVHD using CsA was relatively safe and feasible, this study was underpowered to demonstrate any potential GVM effect of auto-GHVD in myeloma patients undergoing auto-HCT. They further speculated that the decreased incidence of auto-GVHD seen in this study compared to those in patients with breast cancer and AML may have been related to the baseline immune dysfunction that is common in patients with multiple myeloma.
Baron et al. 14 reported the largest phase II clinical study evaluating auto-GVHD. A total of 118 patients undergoing auto-HCT for treatment of breast cancer, myeloma and non-Hodgkin lymphoma were given different transplant regimens with or without TBI plus CsA for auto-GVHD induction. One-third developed clinical evidence of auto-GVHD, confirmed by skin biopsy. This rate was similar to those found by Kennedy. 22 Four patients developed GI tract auto-GVHD, three of whom also had a concurrent rash. Auto-GVHD resolved spontaneously or with the withdrawal of CsA in all but one patient who required temporary treatment with systemic corticosteroids. There was no difference in the rate of nephrotoxicity or hepatotoxicity in patients developing GVHD, compared to those without it. A comparison between CsA-treated patients and historical controls was not undertaken. Factors predictive for the development of auto-GVHD on multivariate analysis were a diagnosis of myeloid malignancy, absence of HLA-DR B6 expression and a high cumulative dose of GM-CSF following auto-HCT. The 5-year overall survival for the entire cohort was 65% for patients without auto-GVHD and 65% for those developing auto-GVHD, and no differences were found on a subgroup analysis taking into account various tumor subtypes. While auto-GVHD was not associated with increased toxicity, appearance of this effect did not correlate with improvement in overall survival.
To investigate the incidence of auto-GVHD using a second calcineurin inhibitor, tacrolimus, Nakamura and associates 40 compared the rates of auto-GVHD in 12 patients with acute leukemia or lymphoma treated with post transplant CsA or tacrolimus. Various conditioning regimens and either autologous bone marrow or peripheral blood stem cells were used. Forty percent of patients developed histologic evidence of auto-GVHD. The time of onset varied from 8 and 25 days post transplantation and lasted several days to 2 weeks. The incidence of auto-GVHD did not differ between those patients receiving CsA or tacrolimus, or between those receiving peripheral blood or bone marrow as the stem cell source.
CsA plus IFN-g
Laboratory and clinical data demonstrate the importance of the HLA-DR antigen (MHC class II) in the cytotoxic effects associated with auto-GVHD. 44 In a phase I study, the Johns Hopkins group tested the hypothesis that HLA-DR upregulation through treatment with IFN-g (Actimmune) would potentiate CsA-induced auto-GVHD. 26 Thirty-six advanced breast cancer patients given cyclophosphamide and thiotepa conditioning also received CsA 2.5 mg/kg/day intravenously for 28 days after auto-HCT and subcutaneous IFN-g 0.025 mg/m 2 every other day from day 7 to 28 after stem cell re-infusion. Auto-GVHD was induced in 56% of patients at a median of 14 days following stem cell re-infusion, an incidence similar to that seen in their previous study that used CsA as a single agent. The incidence of stage II and III acute GVHD rash in the current cohort was 47% compared to 6% in historic controls, suggesting that the co-administration of IFN-g augmented the severity of auto-GVHD compared to CsA alone. Four patients required treatment with topical corticosteroids, and 2 with systemic corticosteroids. In the previous study reported by this group using CsA alone, three patients required topical steroids, and none were treated systemically. 22 There were three toxic deaths in this study, and one patient was found to have CMV pneumonia on autopsy. Maximum creatinine and bilirubin levels in the current investigation were similar to those in the previous CsA alone study conducted by the same group. 22 Hematopoietic reconstitution was more rapid in the current investigation, perhaps because no marrow purging was performed. Septic events were also decreased in this study, likely due to earlier immune reconstitution. HLA-DR levels were studied both pre-and post transplant in four patients, all of whom developed auto-GVHD. In two patients, there was evidence of HLA-DR upregulation after IFN-g treatment, while HLA-DR expression was not increased in two others. After 21 months of follow-up, 53% of patients in the current study remained progression-free, compared with 42% in the previous CsA-alone study-a non-statistically significant difference. The results of this study suggest that IFN-g can be safely used to potentiate CsA-induced auto-GVHD, which is associated with MHC class II upregulation in some patients. Because no comparator group was included, the authors could not speculate as to whether this therapy was associated with a GVM effect or an improvement in progression-free or overall survival.
In a follow up study using CsA and IFN-g post transplant therapy in 50 advanced breast cancer patients, investigators compared the incidence of auto-GVHD using peripheral blood stem cell grafts versus the combination of peripheral blood and marrow grafts. 41 One-third of patients developed clinical auto-GVHD with histopathologic confirmation, and eight patients required treatment with systemic corticosteroids. Two patients developed gastrointestinal GVHD along with skin involvement. One patient with refractory gastrointestinal GVHD succumbed to a CMV infection while receiving treatment with corticosteroids and a calcineurin inhibitor. Toxicity associated with the administration of CsA and IFN-g was otherwise minimal. The incidence of auto-GVHD in this investigation was similar in those subjects receiving peripheral blood stem cell grafts compared to the combination of peripheral blood and marrow grafts, but the overall incidence of auto-GVHD was lower than in previous auto-GVHD studies using bone marrow as the source of stem cells. 26 The authors speculated that the decreased incidence of auto-GVHD seen with peripheral blood stem cell grafts may have been related to the infusion of higher numbers of T cells with potential regulatory properties in this setting. Disease-free and overall survival rates again did not differ based on development of auto-GVHD.
During the investigation, peripheral blood samples were obtained at several time points following auto-HCT and T cells were examined for their ability to lyse autologous pretransplant lymphoblasts and the MHC class II-expressing breast cancer cell line, T47D. T cells from most patients demonstrated cytolytic capability against these two targets in a chromium release assay, irrespective of auto-GVHD status. T cells from patients who developed auto-GVHD tended to acquire auto-cytolytic capability slightly later and for a longer duration compared to T cells from those without auto-GVHD, but these differences were not significantly different. The baseline cytolytic capability of pretransplant T cells against autologous lymphoblasts or T47D cells was not reported. Control samples from patients undergoing auto-HCT, but without CsA and IFN-g treatment were also not examined for evidence of auto-cytolysis. These experiments suggest that T cellmediated autocytolysis may occur in patients following CsA and IFN-g treatment following auto-HCT, but this phenomenon is not necessarily dependent upon development of clinically evident auto-GVHD, and may occur post-auto-HCT in the absence of immunomodulatory therapy.
Vogelsang et al. 24 investigated the effect of marrow purging on auto-GVHD. Sixteen high-risk hematologic malignancy patients were conditioned with either Bu-Cy or Cy-TBI followed by infusion of 4-HC-purged bone marrow and then were given CsA 1 mg/kg/day as well as IFN-g 0.025 mg/m 2 every other day for 10 doses after early engraftment. Only 20% of patients developed clinically significant auto-GVHD manifest by skin involvement and no patient required systemic therapy. The CsA and IFN-g were generally well tolerated, as the reported incidence of grade II or higher nephro-or hepatotoxicity was negligible. There were two toxic deaths related to sepsis and pneumonitis. Time to engraftment was similar to other auto-GVHD studies using 4-HC-purged marrow. Cumulative overall survival appeared to be improved in the cohort of patients receiving CsA and IFN-g compared with historical controls. However, the control group had a median survival of less than 6 months that seems quite low, even for a refractory group of patients. The authors commented that the incidence of auto-GVHD was lower than in other similar studies, perhaps due to the lower dose of effector T cells infused with the purged graft.
Park et al. After approximately 3 years follow-up, the disease-free and overall survival of patients on the study was impressive at 64.4 and 73.1%, respectively, and was not dependent upon auto-GVHD status. Compared with historical controls, post-auto-HCT treatment with CsA and IFN-g appeared to improve survival, but no statistical evidence of this effect was presented in the manuscript.
The future of auto-GVHD
While a fraction of patients with advanced hematological malignancies can be salvaged with auto-HCT, disease recurrence remains the primary cause of death in this population. Auto-HCT recipients often are heavily pretreated with cytotoxic agents and it is unlikely that further intensification of standard therapy will lead to improved cure rates following auto-HCT. Immunotherapy represents a non-cross-resistant therapeutic approach that potentially can reduce relapse through eradication of minimal residual disease that persists following high-dose chemoradiotherapy. The setting of minimal residual disease is an attractive target for immune-based therapies, as they may be most effective at this point. 45 One example of post transplant immunotherapy has been to induce auto-GVHD with CsA. This agent alters central immune tolerance 17, 18 and the preparative regimen depletes regulatory T cells that are important for the maintenance of peripheral tolerance. 20 This dual therapeutic approach has resulted in the development of auto-GVHD in many patients enrolled onto non-randomized clinical trials of CsA with or without IFN-g. The potential clinical benefit of auto-GVHD, however, remains questionable at best. Side effects such as hepatic and renal toxicity as well as opportunistic infections have been reported in some trials. The recent observation of a fatal GVHD-like syndrome after an alemtuzumab containing conditioning regimen for autologous transplant in CLL, serves as a reminder that biologic manipulations can induce unexpected and severe toxicities. 46 
New strategies
Why has this current strategy not resulted in a demonstrable anti-tumor effect? An inferior clinical trial design may be one explanation. While nearly 20 clinical studies have been performed at various transplant centers exploring the use of CsA with or without IFN-g to induce auto-GVHD, most have enrolled less than 20 patients and none have compared this treatment with placebo or no treatment after auto-HCT. Even if auto-GVHD was associated with a small improvement in clinical outcome, it would not be detectable based upon the small numbers of patients enrolled or the lack of a comparator population. The development of larger, phase III studies could perhaps provide an answer as to whether the induction of auto-GVHD is associated with a disease-free or overall survival benefit. However, the preponderance of data from phase I and II studies has been disappointing, and suggests that any survival benefit is at best minimal. Therefore, one must wonder whether it is prudent to continue to invest the time, resources and patients into further exploration of auto-GVHD as it is currently elicited.
Potential aims of future clinical trials might be to explore ways of improving the potency or duration of GVHD, which might in turn lead to a stronger GVM effect. The hypothesis that prolonging the duration of auto-GVHD may lead to improved anti-tumor effects is supported by scientific observations that the in vitro cytolytic capability of autoreactive T cells appears to coincide with clinical symptomatology and rapidly wanes as symptoms dissipate. Most trials to date have treated patients with approximately 1 month of CsA, IFN-g or the combination. It would be interesting to determine whether a longer treatment course would lead to prolonged clinical symptoms and perhaps improved anti-tumor efficacy. This reasoning is similar to the observation that chronic GVHD in the allogeneic setting is much more powerful for GVM than acute GVHD, in part, due to the duration of effect. Alternative agents such as roquinimex, 38 ,47 a quinolone derivative with pleiotropic immunomodulatory effects that increases NK cell number and function, might also be further tested in combination with calcineurin inhibitors, such as CsA, to determine whether they might be capable of augmenting the auto-GVHD effect.
It also has been hypothesized that development of auto-GVHD is dependent upon the absence of host regulatory T cells. 48 The role of Tregs in self-tolerance has been well described. Mice and humans deficient in Tregs develop systemic autoimmunity 49 and Treg depletion potently augments anti-tumor immune responses in murine models. 50 In the post-auto-HCT setting, peripheral regulatory T cells temporarily eliminated by the preparative regimen may permit the development of auto-GVHD, even in the absence of CsA use. 27, 35 The importance of Treg cells within the graft itself is evidenced by the increased rate of spontaneous auto-GVHD in patients receiving CD34 þ positively selected grafts containing low numbers of T cells, specifically Tregs. 13 Because relatively rapid immune reconstitution occurs after auto-HCT, the period of Treg cell depletion is limited; it has been proposed that the resolution of auto-GVHD is dependent upon Treg recovery. 48 One strategy to increase the potency and duration of auto-GVHD might be to use monoclonal antibodies targeted to the CD25 antigen present on most Tregs to deplete them from the autologous graft prior to its reinfusion. This maneuver potentially could license effector CD8 þ T cells to recognize and eliminate tumor cells without Treg-mediated suppression. An alternative option would be to use the anti-IL-2 receptor antibody denileukin diftitox at various time points after auto-HCT to periodically deplete CD25
þ Tregs, a process that has been described in humans receiving renal carcinoma vaccines. 51 Correlative studies should be designed to examine changes in cellular composition and clinical effect. These investigations include the depletion and recovery of Tregs and effector T cells at baseline, as well as prior to and after CD25 þ cell depletion. In vitro cytolytic assays could provide additional clues as to the efficacy of either intensified (CD34 þ selected grafts or CD25 þ cell depletion of the autologous graft) or continued (periodic denileukin diftitox administration) Treg cell depletion.
An alternative approach aimed at inducing a post-auto-HCT anti-tumor immune response might be to treat patients with vaccines to prime the reconstituting immune system against tumor antigens before tolerance can be re-established. For example, Borrello et al.
34 developed a murine model in which animals received an auto-HCT followed by a challenge with syngeneic lymphoma cells, and subsequently, a vaccine consisting of irradiated GM-CSFproducing tumor cells. Mice treated in this manner demonstrated robust immune responses against a model tumor antigen, and demonstrated improved survival rates compared to mice receiving the vaccine without auto-HCT. A similar strategy has been explored in the G-Vax trials, where promising results from early-phase clinical trials of patients with melanoma, as well as prostate, renal cell and non-small cell lung cancer have been demonstrated. 52 Auto-GVHD represents a potentially attractive immunotherapeutic strategy to reduce relapse following auto-HCT. To date, the evidence has not suggested improved clinical outcomes for patients who develop auto-GVHD, despite hints of fleeting anti-tumor activity. 44 Larger and controlled studies can help answer the efficacy question of current methods of auto-GVHD induction with CsA. If investigators are able to increase the duration and potency of auto-GVHD, this effect will likely be achieved at a cost, such as an increase in infectious and other risks associated with GVHD. 53 In the future, prolonged therapy with CsA, exploration of newer immunomodulatory agents and Treg cell depletion may augment the auto-GVHD effect and perhaps potentiate anti-tumor efficacy.
